Mereo BioPharma (MREO) Return on Sales (2023 - 2025)

Mereo BioPharma (MREO) has reported Return on Sales for 3 consecutive years, with 1.05% the latest figure, recorded in Q4 2025.

• Quarterly Return on Sales changed N/A year-over-year to 1.05% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 1.05% (changed N/A YoY) and the FY2025 annual result came in at 1.05%, changed N/A from the prior year.
• Return on Sales steadied at 1.05% in Q4 2025 per MREO's latest filing, from 1.05% in the prior quarter.
• Over the last five years, Return on Sales for MREO reached as high as 0.02% in Q1 2024 and fell as low as 1.05% in Q3 2025.
• A 3-year average of 0.47% and a median of 0.37% in 2024 frame the typical range for Return on Sales.
• The largest YoY upside for Return on Sales was 8 bps in 2025 against a maximum downside of 60 bps in 2025.
• Year by year, Return on Sales stood at 0.09% in 2023, then tumbled by 397 bps to 0.45% in 2024, then plunged by 131 bps to 1.05% in 2025.
• According to Business Quant data, Return on Sales over the past three periods registered 1.05%, 1.05%, and 0.29% for Q4 2025, Q3 2025, and Q2 2025 respectively.